KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study.

Reiko Horikawa, Toshiaki Tanaka, Yukihiro Hasegawa, Tohru Yorifuji, David Ng, Ron G Rosenfeld, Yuko Hoshino, Akifumi Okayama, Nozomi Ebata, Masayoshi Hosoi, Shinichi Nakamuta, Roy Gomez, Aleksandra Pastrak, Orlando Castellanos

Endocr J 73(1) 21-32

PMID41183961
PMCIDPMC12819071
DOI10.1507/endocrj.EJ24-0625
发表日期2025-11-03
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图;另有 1 张未列出。
摘要

摘要

Somatrogon is a long-acting recombinant human growth hormone approved in several countries, including Japan, for the treatment of children with growth hormone deficiency (GHD). In this study (Clinicaltrials.gov:NCT03874013) Japanese patients with GHD initially received once-weekly somatrogon or once-daily somatropin (0.175 mg/kg/week) for 12 months in the main study period; those who completed the main study were eligible to enroll in a single-arm, 3-year open-label extension (OLE) and receive once-weekly somatrogon (0.66 mg/kg/week). The primary endpoints of the OLE included annualized height velocity (HV), change in height standard deviation score (SDS), and safety. Of 43 patients who completed the main study, 42 continued into the OLE and 40 completed the OLE. Patients were analyzed by treatment received (somatrogon vs. somatropin) during the main study. Mean (SD) HV at OLE baseline was higher in patients originally randomized to somatrogon vs. somatropin (9.78 [1.59] vs. 7.70 [1.10] cm/year); mean HV was similar between original treatment groups for all other OLE timepoints. Mean height SDS increased from main study baseline through the end of the OLE in both treatment groups. During the OLE, 22 (100%) somatrogon-treated patients and 18 (90%) somatropin-treated patients reported treatment-emergent adverse events (TEAEs). Most TEAEs were mild or moderate in severity and no patients discontinued from the OLE or required dose reductions due to TEAEs. Up to 4 years of treatment with once-weekly somatrogon resulted in improved growth response and was well tolerated in Japanese patients with pediatric GHD, including patients who switched to somatrogon from once-daily somatropin.Clinialtrials.gov:NCT03874013.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Patient evaluation groups and disposition AE, adverse event; FAS, full analysis set; OLE, open-label extension.
非 KM Figure
Fig. 2Annualized height velocity (mean ± SD) for each 12-month period *Month 12 is the OLE baseline. During the OLE, the total number of patients who were evaluable for annualized HV at 24 months, 36 months, and 48 months, were 41 patients, 41 patients and 16 patients, respectively. OLE, open-label extension.
非 KM Figure
Fig. 3Change in height SDS (mean ± SD) for each 12-month period (from baseline of main study period) *Month 12 is the OLE baseline. During the OLE, the total number of patients who were evaluable for height SDS at 24 months, 36 months, and 48 months, were 41 patients, 41 patients and 16 patients, respectively. OLE, open-label extension; SDS, standard deviation score.
非 KM Figure
Fig. 4Change in bone maturation (mean ± SD) for each 12-month period Bone maturation was calculated as bone age divided by chronological age. Change in bone maturation at month 12 is relative to the main study period baseline. *Month 12 is the OLE baseline. OLE, open-label extension.
非 KM Figure
Fig. 5(A) IGF-1 change from baseline (median, minimum to maximum) and (B) IGF-1 SDS levels (median, minimum to maximum) on day 4 (–1) after somatrogon dosing across study visits Median (minimum to maximum) IGF-1 SDS at month 13 for patients originally randomized to somatropin was 1.3 (–1.1 to 3.4). *Month 12 is the OLE baseline. IGF-1, insulin-like growth factor 1; OLE, open-label extension; SDS, standard deviation score.
非 KM Figure
Graphical Abstract无图注
非 KM Figure